<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636725</url>
  </required_header>
  <id_info>
    <org_study_id>20150932</org_study_id>
    <nct_id>NCT02636725</nct_id>
  </id_info>
  <brief_title>Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas</brief_title>
  <official_title>A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonathan Trent, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test if Axitinib together with Pembrolizumab can&#xD;
      slow tumor growth and know the side effects of the combination treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 19, 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">December 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Participants Achieving Progression-Free Survival (PFS) at 3 Months</measure>
    <time_frame>3 Months</time_frame>
    <description>Rate of participants who are disease progression free 3 months after initiation of therapy. Disease progression will be evaluated from imaging measures using the Response Evaluation Criteria for Solid Tumors (RECIST) 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Participants Achieving Objective Response (ORR)</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Objective Response Rate (ORR) is defined as achieving complete response (CR) or partial response (PR) from imaging measures using (RECIST) 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Participants Achieving Clinical Benefit Response (CBR)</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>CBR is defined as achieving complete response (CR), partial response (PR) or stable disease (SD) from imaging measures using (RECIST) 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>OS is defined as time from study treatment initiation to first occurrence of progression by RECIST v1.1 or death or censuring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Dose Limiting Toxicities (DLT)</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>DLTs will be evaluated by treating physician using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Alveolar Soft Part Sarcoma</condition>
  <condition>Soft Tissue Sarcomas</condition>
  <arm_group>
    <arm_group_label>Axitinib Plus Pembrolizumab Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive combination treatment of Axitinib plus Pembrolizumab for up to 2 years followed by monotherapy of Axitinib until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axitinib Plus Pembrolizumab Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohort for up to 10 additional patients with alveolar soft part sarcoma. Participants in this group will receive combination treatment of Axitinib plus Pembrolizumab for up to 2 years followed by monotherapy of Axitinib until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>5 mg tablets twice daily oral dose administered for 7 consecutive weeks on Cycle 1. A safety lead-in consisting of the initial five patients, intrapatient dose escalation of Axitinib will be permitted based on the absence of predefined toxicities. Twice daily oral dose between 2 mg to 10 mg Axitinib tablets will be administered on subsequent 6 week cycles until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.</description>
    <arm_group_label>Axitinib Plus Pembrolizumab Expansion Cohort</arm_group_label>
    <arm_group_label>Axitinib Plus Pembrolizumab Group</arm_group_label>
    <other_name>Inlyta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200 mg intravenous infusion administered every 21 weeks beginning week 2 of Cycle 1 for a maximum of up to 2 years or until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.</description>
    <arm_group_label>Axitinib Plus Pembrolizumab Expansion Cohort</arm_group_label>
    <arm_group_label>Axitinib Plus Pembrolizumab Group</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have histologically confirmed sarcoma with pathology review required for&#xD;
             any outside samples.&#xD;
&#xD;
          2. The following histologies may be enrolled without prior treatment:&#xD;
&#xD;
               -  alveolar soft part sarcoma,&#xD;
&#xD;
               -  clear cell sarcoma,&#xD;
&#xD;
               -  epithelioid hemangioendothelioma, and&#xD;
&#xD;
               -  chordoma.&#xD;
&#xD;
          3. The following histologies may be enrolled ONLY if refractory to anthracycline-based&#xD;
             chemotherapy or if the patient refuses to undergo standard of care treatment:&#xD;
&#xD;
               -  synovial sarcoma,&#xD;
&#xD;
               -  rhabdomyosarcoma,&#xD;
&#xD;
               -  malignant peripheral nerve sheath tumors,&#xD;
&#xD;
               -  dedifferentiated, pleomorphic or myxoid/round cell liposarcoma,&#xD;
&#xD;
               -  leiomyosarcoma,&#xD;
&#xD;
               -  malignant phylloides tumor,&#xD;
&#xD;
               -  high grade undifferentiated pleomorphic sarcomas (HGUPS/MFH),&#xD;
&#xD;
               -  angiosarcoma,&#xD;
&#xD;
               -  spindle cell sarcoma, not otherwise specified (NOS)&#xD;
&#xD;
               -  malignant myoepithelioma.&#xD;
&#xD;
          4. The following histologies may be enrolled ONLY if refractory to at least one line of&#xD;
             chemotherapy or if the patient refuses to undergo standard of care treatment:&#xD;
&#xD;
               -  solitary fibrous tumor/hemangiopericytoma.&#xD;
&#xD;
          5. The following histologies may be enrolled ONLY if refractory to at least first-line&#xD;
             targeted therapy or if the patient refuses to undergo standard of care treatment:&#xD;
&#xD;
               -  gastrointestinal stromal tumors,&#xD;
&#xD;
               -  extraskeletal myxoid chondrosarcoma,&#xD;
&#xD;
               -  PEComa.&#xD;
&#xD;
          6. Primary tumors of bone including Ewing's sarcoma, osteosarcoma, and dedifferentiated&#xD;
             chondrosarcoma may only be enrolled if there are measurable target lesions occurring&#xD;
             in soft tissue and they are refractory to standard of care anthracycline-based&#xD;
             chemotherapy.&#xD;
&#xD;
          7. Any other histology or standard of care therapy not specifically addressed will be&#xD;
             reviewed by the principal investigator and pathologist for final determination of&#xD;
             eligibility.&#xD;
&#xD;
          8. Measurable disease as defined by RECIST v1.1 (provided in Section 14.0).&#xD;
&#xD;
          9. Radiographic progression as defined by RECIST v1.1, based on comparison between two&#xD;
             radiographic studies no greater than 6 months apart.&#xD;
&#xD;
         10. Inability to undergo complete resection of the disease by surgery.&#xD;
&#xD;
         11. Adequate organ function as defined:&#xD;
&#xD;
               -  Hematological&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) ≥1,000 / microliter (mcL)&#xD;
&#xD;
                    -  Platelets ≥75,000 / mcL&#xD;
&#xD;
                    -  Hemoglobin ≥8 g/dL without transfusion or erythropoietin (EPO) dependency&#xD;
                       (within 7 days of assessment)&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
                    -  Serum creatinine ≤1.5 X upper limit of normal (ULN) OR Measured or&#xD;
                       calculated creatinine clearance ≥ 60 mL/min for subject with creatinine&#xD;
                       levels &gt; 1.5 X institutional ULN. (GFR can also be used in place of&#xD;
                       creatinine or CrCl). Creatinine clearance should be calculated per&#xD;
                       institutional standard.&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
                    -  Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects&#xD;
                       with total bilirubin levels &gt; 1.5 ULN.&#xD;
&#xD;
                    -  Aspartate Aminotransferase (AST/SGOT) and Alanine Transaminase (ALT/SGPT) ≤&#xD;
                       2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases.&#xD;
&#xD;
                    -  Albumin &gt;2.5 mg/dL&#xD;
&#xD;
               -  Coagulation&#xD;
&#xD;
                    -  International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN&#xD;
                       unless subject is receiving anticoagulant therapy as long as PT or PTT is&#xD;
                       within therapeutic range of intended use of anticoagulants.&#xD;
&#xD;
                    -  Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is&#xD;
                       receiving anticoagulant therapy as long as PT or PTT is within therapeutic&#xD;
                       range of intended use of anticoagulants.&#xD;
&#xD;
         12. Age ≥ 16 years.&#xD;
&#xD;
         13. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
         14. Patients must consent and be willing to undergo three core needle biopsies at&#xD;
             baseline, prior to starting Cycle 3, and at off-study. At least one tumor site must be&#xD;
             amenable to biopsy in the judgment of the interventional radiologist.&#xD;
&#xD;
         15. Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to receiving the first dose of study medication. If&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required.&#xD;
&#xD;
         16. Females of child bearing potential that are sexually active must agree to either&#xD;
             practice 2 medically accepted highly effective methods of contraception at the same&#xD;
             time or abstain from heterosexual intercourse from the time of signing the informed&#xD;
             consent through 120 days after the last dose of study drug. See Appendix G for&#xD;
             protocol-approved highly effective methods of contraceptive combinations. Subjects of&#xD;
             childbearing potential are those who have not been surgically sterilized or have not&#xD;
             been free from menses for &gt; 1 year.&#xD;
&#xD;
               -  Negative test for pregnancy is required of females of child-bearing potential; A&#xD;
                  female of child bearing potential is any woman, regardless of sexual orientation&#xD;
                  or whether they have undergone tubal ligation, who meets the following criteria:&#xD;
                  1. has not undergone a hysterectomy or bilateral oophorectomy; or 2. has not been&#xD;
                  naturally postmenopausal for at least 24 consecutive months (i.e., has had menses&#xD;
                  at any time in the preceding 24 consecutive months or 730 days).&#xD;
&#xD;
               -  Conception while on treatment must be avoided&#xD;
&#xD;
         17. Male subjects should agree to use an adequate method of contraception starting with&#xD;
             the first dose of study therapy through 120 days after the last dose of study therapy.&#xD;
             Prior history of vasectomy does NOT replace requirement for contraceptive use.&#xD;
&#xD;
         18. Suitable venous access to allow for all study related blood sampling&#xD;
&#xD;
         19. Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
         20. For minors that are 16 to 18 years of age, assent and parental (or legally acceptable&#xD;
             representative) written informed consent must be obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior therapy with axitinib. Patients are permitted to have received prior tyrosine&#xD;
             kinase inhibitor (TKI) therapy including imatinib, sunitinib, pazopanib, or similar.&#xD;
             Patients may have received prior Programmed death 1 (PD-1)/Programmed death-ligand 1&#xD;
             (PD-L1) directed therapy.&#xD;
&#xD;
          2. Hypersensitivity to axitinib, pembrolizumab or any of its excipients.&#xD;
&#xD;
          3. Patients may not be receiving any other investigational agents (within 4 weeks prior&#xD;
             to Cycle 1, day 1).&#xD;
&#xD;
          4. Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to Cycle 1, day 1 or&#xD;
             has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents&#xD;
             administered more than 4 weeks earlier.&#xD;
&#xD;
          5. Patient has had prior chemotherapy, targeted small molecule therapy, or radiation&#xD;
             therapy within 2 weeks prior to Cycle 1, Day 1 or has not recovered (i.e., ≤ Grade 1&#xD;
             or at baseline) from adverse events due to agents administered more than 4 weeks&#xD;
             earlier. Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may&#xD;
             qualify for the study. Note: If subject received major surgery, they must have&#xD;
             recovered adequately from the toxicity and/or complications from the intervention&#xD;
             prior to starting therapy.&#xD;
&#xD;
          6. Additional known malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, or squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy, or in situ cervical cancer.&#xD;
&#xD;
          7. Patients with end-organ dysfunction as defined in inclusion criterion (i.e. #11&#xD;
             above).&#xD;
&#xD;
          8. Patients with bone-only lesions.&#xD;
&#xD;
          9. Patients with underlying immune deficiency, chronic infections including HIV,&#xD;
             hepatitis, or tuberculosis (TB) or autoimmune disease.&#xD;
&#xD;
         10. Patients with underlying hematologic issues including bleeding diathesis, known&#xD;
             previous GI bleeding requiring intervention within the past 6 months, active pulmonary&#xD;
             emboli or deep vein thromboses (DVT) that are not stable on anticoagulation regimen.&#xD;
&#xD;
         11. Has known history of, or any evidence of active, non-infectious pneumonitis.&#xD;
&#xD;
         12. Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis or leptomeningeal disease. Subjects with previously treated brain&#xD;
             metastases may participate provided they are stable (without evidence of progression&#xD;
             by imaging for at least four weeks prior to the first dose of trial treatment and any&#xD;
             neurologic symptoms have returned to baseline), have no evidence of new or enlarging&#xD;
             brain metastases, and are not using steroids for at least 7 days prior to trial&#xD;
             treatment. This exception does not include carcinomatous meningitis which is excluded&#xD;
             regardless of clinical stability.&#xD;
&#xD;
         13. Concomitant (or receipt of) treatment with medications that may affect the metabolism&#xD;
             of pembrolizumab and/or axitinib within 7 days prior to Cycle 1, day 1 of axitinib.&#xD;
&#xD;
         14. Has received a live vaccine within 30 days of planned start of study therapy. Note:&#xD;
             Seasonal influenza vaccines for injection are generally inactivated flu vaccines and&#xD;
             are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live&#xD;
             attenuated vaccines, and are not allowed.&#xD;
&#xD;
         15. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
         16. Any uncontrolled, intercurrent illness including but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia&#xD;
&#xD;
         17. Prolonged corrected QT (QTc) interval on Screening EKG &gt;475 ms.&#xD;
&#xD;
         18. Ejection Fraction &lt;40% by 2D echocardiogram (ECHO) at Screening.&#xD;
&#xD;
         19. Any serious medical or psychiatric illness/condition including substance use disorders&#xD;
             likely in the judgment of the Investigator(s) to interfere or limit compliance with&#xD;
             study requirements/treatment.&#xD;
&#xD;
         20. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan C Trent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Jonathan Trent, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Advanced Alveolar Soft Part Sarcoma</keyword>
  <keyword>ASPS</keyword>
  <keyword>STS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Alveolar Soft Part</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 1, 2021</submitted>
    <returned>October 29, 2021</returned>
    <submitted>October 29, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

